negatively correlated with serum DKK1 and sclerostin levels (r=-0.363; p=0.049 and r=-0.416; p=0.022, respectively) in the SS group. Moreover, in the salivary gland tissues, the positivities of p=0.182) and p=0.345) were relatively higher in the SS group compared to the control group, respectively. Conclusions: According to the best of our knowledge, this study is the first study evaluating the activity of Wnt/β-catenin pathway in the primary SS. The altered serum levels of DKK1 and sclerostin in primary SS and SLE is suggest that Wnt/β-catenin pathway is affected in these inflammatory diseases. Salivary DKK1 level is increased in primary SS in contrast to SLE. On the other hand, Wnt-1 and Wnt-3a expressions on the salivary gland are increased in primary SS. Therefore, it may be concluded that Wnt/β-catenin pathway acts pathogenic roles on the glandular inflammation. Background: Reduction in capillaries number is the defining feature of microvascular disease in Systemic Sclerosis (SSc) and it concurs to the ischemic manifestations of the disease. Digital Ulcers (DUs) are the major complication of ischemic peripheral vasculopathy. Dynamic optical coherence tomography (D-OCT) is a recently developed imaging technique that allows non-invasive in vivo study of the microvasculature of the skin. In addition to the skin architecture and vessels morphology, it offers information about flow status, allowing the functional and quantitative evaluation of the microcirculation. Objectives: To determine the face and content validity of D-OCT as outcome measure of the skin microvascular disease, assuming the presence of current DUs, distal to the DIP joints, as gold standard for ischemic peripheral vasculopathy in SSc. Methods: A total of 54 patients were enrolled in this cross-sectional study, including 18 SSc patients with current DUs (DU group); 18 SSc patients without current DUs (no DU group) and 18 patients with Raynaud's phenomenon and SSc specific ANA, who did not fulfilled ACR/EULAR 2013 classification criteria (SRP group). For each patient, we performed a D-OCT scan on both index and middle fingers, on the dorsal aspect of the second phalanx, employing Vivosight Scanner (Michelson Diagnostics) . The speckle variance signal of D-OCT images within the first mm of skin depth was extracted, quantified as area under the curve (AUC) and defined as Micro Vascular Flow (MVF). MVF comparison between the groups was done using parametric or nonparametric tests as appropriate. Statistical Analysis was performed with SPSS V.22. Results: All three groups were comparable in terms of age and gender distribution (p>0.80 for both) as well as disease duration and clinical subset between the two SSc groups (p=0.839 and p=0.646, resp.). With a scan time <1 minute, D-OCT allowed the visualization and quantification of capillaries within the first millimeter of skin depth (Figure 1 ). The distribution of MVF was not significantly different among the four fingers within each group (DU group: p=0.459, no DU group: p=0.953 and SRP group: p=0.616). On the contrary, the distribution and median MVF for all fingers was significantly different among the 3 groups: DU group=0.134 (IQR 0.121-0.134), no DU group=0.153 (IQR 0.132-0.153) and SRP group=0.167 (IQR 0.148-0.167) (p<0.0001), as well as in the DU group vs. no DU group (p<0.001) or DU vs SRP group (p<0.001). Further, sub analysis of the DU group showed that 10 of the total 20 DUs were on the left index finger. Within this subgroup the MVF of patients on Sildenafil (n=6) was significantly higher than the rest of the group (0.148±0.021 vs. 0.113±0.019, p=0.03).
Conclusions:
MVF assessed by D-OCT is a quantitative, non-invasive surrogate outcome measure of severe peripheral ischemic vasculopathy in SSc. Longitudinal studies assessing its sensitivity to change will inform whether MVF can be used as end point of skin microvascular involvement in SSc. Background: Polymyalgia rheumatica (PMR) is a systemic inflammatory disorder with unknown etiology and overlapping symptoms with giant cell arthritis and late-onset rheumatoid arthritis (RA). To date, no proteomics studies have been performed on PMR patients, and the number of biomarker studies remain limited. Objectives: The primary aim of this study was to thoroughly investigate the corticosteroid treatment serum proteome of PMR with a focus on acute-phase reactions, complement system, and cytokines. Methods: Filter-aided sample preparation for mass spectrometry, cell free DNA (cfDNA) assay, and 10plex cytokine assay were applied to PMR serum samples from the same patients before and after treatment, DMARD-naïve RA patients, and healthy controls.
Results:
The core serum proteomes of the four groups were remarkably similar, and consisted of >200 proteins, which included acute-phase reactants, coagulation and complement proteins (figure), immunoglobulins, and apolipoproteins, and several more. Acute Phase Serum Amyloid A (SAA1) was differentially less abundant after PMR treatment, and CRP (after adjusting for two patients with low baseline CRP). cfDNA were more abundant in both groups of PMR compared to healthy controls. Complement factors were narrowly distributed and not affected by PMR treatment. The individual serum proteome of each PMR patient provided more than 100 differentially abundant proteins, and highlights the heterogeneity of patients.
Conclusions:
We have established the core serum proteome of PMR in response to treatment, and compared it with RA and healthy controls. The results suggest a functional role of SSA1, and increased cfDNA in the pathogenesis of PMR indicates the activation of NETs. Background: Adalimumab (Ada) has proven effective in treating rheumatoid arthritis (RA) and spondyloarthropathies (SpA), although approximately 30% of responders will present secondary clinical failure. Immunocomplex formation between antibodies to Ada (ATA) and Ada can increase drug clearance. Most of the assays to measure ATA present drug interference. Currently, different assays are available to measure total ATA (free and complexed). Objectives: To compare the detection of ATA along Ada treatment between two assays: one drug-sensitive and another drug-tolerant assay. Study the association of ATA with the clinical status. Methods: This is a prospective observational study with 63 patients with rheumatic diseases under Ada treatment enrolled at Biological Therapy Unit of Hospital La Paz. Serum Ada levels were measured by ELISA and serum ATA levels by two assays: an in-house two-site (bridging) ELISA (bELISA) to detect uncomplexed ATA (free ATA) and a drug-tolerant assay developed by ImmundiagnostikÒ (Bensheim, Germany) (IDK) to measure simultaneously free and complexed ATA (total ATA). Samples were evaluated at 0, 0.2, 0.5, 1, 1.5 and 2 years after Ada initiation. Results: Out of the 63 studied patients, 12 (19%) had RA and the rest (51, 81%) had different spondyloarthropathies (24, 38%) ankylosing spondylitis, 9 (14%) psoriatic arthritis, 14 (22%) undifferentiated spondyloarthritis and 4 (6%) spondyloarthritis associated with inflammatory bowel disease).Thirty-one patients (49%) received concomitant methotrexate (26% RA patients and 74% SpA patients), 13 (21%) received another DMARDs associated to Ada and 19 (30%) were on monotherapy.Out of the 63 patients, in 27 (43%) no ATA were detected. Thirty six patients (57%), were IDK+ and 12 patients (19%) were bELISA+ (all of them IDK+).The presence of ATA by bELISA was associated with absence of serum Ada levels. However, most (78%) samples with complexed ATA had low circulating Ada levels (1.65 mg/ml in ATA+ vs 6.25 mg/ml in ATA-, p<0.0001). ATA appeared by IDK at earlier treatment stages than by bELISA, statistically different at all studied time points.In patients who dropped-out (30 patients, 48%) ATA detection was frequent and significant by both methods.Ten patients (33%) bELISA ATA+ dropped-out vs 2 patients bELISA ATA+ in those who continued treatment (p<0.0001). Twenty four patients (80%) IDK ATA+ dropped-out vs 12 patients (36%) who continued treatment (p<0.0001). The percentage of ATA detected by IDK was higher than by bELISA, with a tendency of more IDK ATA+ among patients with less survival (24,80% IDK positive vs 10,33% bELISA +; p=0.06) Conclusions: ATA are detected by a drug-tolerant assay at earlier stages of treatment than by bELISA. The antibodies formed early are associated with lower levels of circulating Ada, indicating higher drug clearance. This information might be useful to implement the Therapeutic Drug Monitoring. However, the detection of early complexed ATA has not demonstrated a significant advantage over the bELISA to predict treatment survival.
